BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 07 2025 - 6:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that
the company will present at the 43rd Annual J.P. Morgan Healthcare
Conference in San Francisco on Tuesday, January 14, 2025, at 6:00
p.m. ET.
Link to the live audio webcast and replay of the
presentation may be accessed in the Investors & Media section
of BioCryst’s website at www.biocryst.com.
About BioCryst
PharmaceuticalsBioCryst Pharmaceuticals is a global
biotechnology company with a deep commitment to improving the lives
of people living with hereditary angioedema and other rare
diseases. BioCryst leverages its expertise in structure-guided drug
design to develop first-in-class or best-in-class oral
small-molecule and protein therapeutics to target
difficult-to-treat diseases. BioCryst has commercialized ORLADEYO®
(berotralstat), the first oral, once-daily plasma kallikrein
inhibitor, and is advancing a pipeline of small-molecule and
protein therapies. For more information, please visit
www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Dec 2024 to Jan 2025
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Jan 2024 to Jan 2025
